Genetics, Genomics & Molecular Diagnostics News

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.

Executives from Genomic Health, Meridian Bioscience, and Qiagen provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.

Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.

The company also announced a 5 percent increase in preliminary fourth quarter revenues, to $619 million and above analysts' estimates.

The deal, completed this month with cash reserves for an undisclosed price, adds scalability and multi-omics analysis to Qiagen's bioinformatics portfolio.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.

Humanized NSG and NSG-SGM3 mice are a new preclinical bridge for immune-oncology therapies. Humanized mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.

Genotoxicity workflows performed manually are subject to workflow bottlenecks, where the throughput is inherently limited, and active time spent performing the tests reduces the lab’s overall efficiency. Additionally, variability associated with operator technique and laboratory conditions could lead to a loss in precision, or worse, systematic errors that can skew results. This article demonstrates automated imaging as it pertains to the comet and gamma-H2AX assays in order to simplify genotoxicity assay workflows and provide robust results.

Stringent guidelines of quality assurance and control (QA/QC) serve as the foundation for dependable and reproducible results in any analytical endeavor. Here we highlight step-by-step, the measures implemented by Myriad RBM that take Luminex xMAP technology to a high level of reproducibility and ruggedness. The Myriad RBM platform combines the sensitivity and dynamic range of microsphere-based immuno-multiplexing with the precision and dependability of automated liquid handling.